Catalyst Calendar

Thu, Sep 3, 2026

1 updates

7:00 AM

Climb Bio Announces CLYM116 Phase 1 Data Demonstrating Prolonged Half-Life and Best-In-Class APRIL Suppression Supporting Every-12-Week Dosing in IgA Nephropathy

~29-day half-life Single 320 mg dose of CLYM116 drove near-complete APRIL suppression and 60-75% IgA/Gd-IgA1 suppression through 12 weeks CLYM116 generally well-tolerated, with no serious adverse events, dose-limiting toxicities, or hypogammaglobulinemia Phase 2 NAVIGATE-2 trial in IgA nephropathy

Trial Results • Phase 1Phase 1 data release Thu, Sep 3, 2026climbbio.com

Wed, Sep 2, 2026

1 updates

CLYM

7:00 AM

Climb Bio to Present at Upcoming Investor Conferences

WELLESLEY HILLS, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that members of its executive team will participate in the upcoming conferences

climbbio.com

Thu, Aug 6, 2026

1 updates

CLYM

7:00 AM

Climb Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates

CLYM116 Phase 1 data in healthy volunteers to be presented at R&D Spotlight Event on September 3, 2026 Anticipate CLYM116 Phase 2 trial in IgA nephropathy to initiate dosing in Q3 2026 Budoprutug clinical programs continue to advance, with data expected from pMN, ITP, and SLE studies in Q4 2026

Results Call • Phase 1Results call Thu, Sep 3, 2026climbbio.com